{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:39:28Z","timestamp":1790368768191,"version":"4.1.0"},"reference-count":117,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>COVID-19 is spreading worldwide at disturbing rates, overwhelming global healthcare. Mounting death cases due to disease complications highlight the necessity of describing efficient drug therapy strategies for severe patients. COVID-19 severity associates with hypercoagulation and exacerbated inflammation, both influenced by ACE2 downregulation and cytokine storm occurrence. In this review, we discuss the applicability of the anticoagulant heparin and the anti-inflammatory corticosteroid dexamethasone for managing severe COVID-19 patients. The upregulated inflammation and blood clotting may be mitigated by administrating heparin and its derivatives. Heparin enhances the anticoagulant property of anti-thrombin (AT) and may be useful in conjunction with fibrinolytic drugs for severe COVID-19 patients. Besides, heparin can also modulate immune responses, alleviating TNF-\u03b1-mediated inflammation, impairing IL-6 production and secretion, and binding to complement proteins and leukotriene B<jats:sub>4<\/jats:sub> (LTB<jats:sub>4<\/jats:sub>). Moreover, heparin may present anti-SARS-CoV-2 potential once it can impact viral infectivity and alter SARS-CoV-2 Spike protein architecture. Another feasible approach is the administration of the glucocorticoid dexamethasone. Although glucocorticoid's administration for viral infection managing is controversial, there is increasing evidence demonstrating that dexamethasone treatment is capable of drastically diminishing the death rate of patients presenting with Acute Respiratory Distress Syndrome (ARDS) that required invasive mechanical ventilation. Importantly, dexamethasone may be detrimental by impairing viral clearance and inducing hyperglycemia and sodium retention, hence possibly being deleterious for diabetics and hypertensive patients, two major COVID-19 risk groups. Therefore, while heparin's multitarget capacity shows to be strongly beneficial for severe COVID-19 patients, dexamethasone should be carefully administered taking into consideration underlying medical conditions and COVID-19 disease severity. Therefore, we suggest that the multitarget impact of heparin as an anti-viral, antithrombotic and anti-inflammatory drug in the early stage of the COVID-19 could significantly reduce the need for dexamethasone treatment in the initial phase of this disease. If the standard treatment of heparins fails on protecting against severe illness, dexamethasone must be applied as a potent anti-inflammatory shutting-down the uncontrolled and exacerbated inflammation.<\/jats:p>","DOI":"10.3389\/fmed.2021.615333","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T04:32:51Z","timestamp":1619152371000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["The Use of the Anticoagulant Heparin and Corticosteroid Dexamethasone as Prominent Treatments for COVID-19"],"prefix":"10.3389","volume":"8","author":[{"given":"Helo\u00edsa Antoniella","family":"Braz-de-Melo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Socorro","family":"Faria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Pasquarelli-do-Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor de Oliveira","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary P.","family":"Kobinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly Grace","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00134-020-06062-x","article-title":"High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study","volume":"46","author":"Helms","year":"2020","journal-title":"Intensive Care Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1016\/j.jacc.2020.03.031","article-title":"Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic","volume":"75","author":"Driggin","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1681\/ASN.2020040419","article-title":"Acute kidney injury in COVID-19: emerging evidence of a distinct pathophysiology","volume":"31","author":"Batlle","year":"2020","journal-title":"J Am Soc Nephrol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1590\/s1678-9946202062043","article-title":"Prevalence of comorbidities in patients and mortality cases affected by SARS-CoV2: a systematic review and meta-analysis","volume":"62","author":"Espinosa","year":"2020","journal-title":"Rev Inst Med Trop S\u00e0o Paulo."},{"key":"B5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1128\/MMBR.05015-11","article-title":"Into the eye of the cytokine storm","volume":"76","author":"Tisoncik","year":"2012","journal-title":"Microbiol Mol Biol Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41577-020-0343-0","article-title":"COVID-19: the vasculature unleashed","volume":"20","author":"Teuwen","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1113\/expphysiol.2007.040048","article-title":"The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice","volume":"93","author":"Imai","year":"2008","journal-title":"Exp Physiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1056\/NEJMc2007575","article-title":"Coagulopathy and antiphospholipid antibodies in patients with Covid-19","volume":"382","author":"Zhang","year":"2020","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/bjh.14885","article-title":"The role of heparin in sepsis: much more than just an anticoagulant","volume":"179","author":"Li","year":"2017","journal-title":"Br J Haematol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2001365","DOI":"10.1183\/13993003.01365-2020","article-title":"Pulmonary embolism in patients with COVID-19 pneumonia","volume":"56","author":"Bompard","year":"2020","journal-title":"Eur Respir J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/jamacardio.2020.1105","article-title":"Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality","volume":"323","author":"Bonow","year":"2020","journal-title":"JAMA Cardiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1161\/CIRCRESAHA.116.306853","article-title":"Cross talk pathways between coagulation and inflammation","volume":"118","author":"Foley","year":"2016","journal-title":"Circ Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"198070","DOI":"10.1016\/j.virusres.2020.198070","article-title":"COVID-19: review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking","volume":"286","author":"Magro","year":"2020","journal-title":"Virus Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1046\/j.1365-2141.2001.03061.x","article-title":"Interleukin 6 and haemostasis","volume":"115","author":"Kerr","year":"2001","journal-title":"Br J Haematol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1182\/blood-2002-02-0620","article-title":"Platelet activation induced by human antibodies to interleukin-8","volume":"101","author":"Regnault","year":"2003","journal-title":"Blood."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.36416\/1806-3756\/e20200168","article-title":"COVID-19 pneumonia : a risk factor for pulmonary thromboembolism?","volume":"46","author":"Filisbino","year":"2020","journal-title":"J Bras Pneumol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1016\/S2352-3026(20)30109-5","article-title":"Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19","volume":"7","author":"Wang","year":"2020","journal-title":"Lancet Haematol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/S2213-2600(20)30216-2","article-title":"COVID-19 cytokine storm: the interplay between inflammation and coagulation","volume":"2019","author":"Jose","year":"2019","journal-title":"Lancet Respir."},{"key":"B21","first-page":"133","article-title":"The discovery of heparin","volume":"8","author":"Hoffer","year":"1993","journal-title":"J Orthomol Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0889-8588(02)00091-6","article-title":"Heparin, low-molecular-weight heparins, and heparin pentasaccharide basic and clinical differentiation","volume":"17","author":"Hoppensteadt","year":"2003","journal-title":"Hematol Oncol Clin North Am."},{"key":"B23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4103\/0974-2700.76843","article-title":"Heparin-induced thrombocytopenia","volume":"4","author":"Sancar Eke","year":"2011","journal-title":"J Emerg Trauma Shock"},{"key":"B24","doi-asserted-by":"publisher","first-page":"5275","DOI":"10.3390\/ijms20215275","article-title":"Anticoagulants and osteoporosis","volume":"20","author":"Signorelli","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph9030038","article-title":"Heparin: past, present, and future","volume":"9","author":"Oduah","year":"2016","journal-title":"Pharmaceuticals."},{"key":"B26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40138-013-0014-6","article-title":"Anticoagulants: a review of the pharmacology, dosing, and complications","volume":"1","author":"Alquwaizani","year":"2013","journal-title":"Curr Emerg Hosp Med Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2174\/157016309789869001","article-title":"Therapeutic use of heparin beyond anticoagulation","volume":"6","author":"Ludwig","year":"2009","journal-title":"Curr Drug Discov Technol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/gut.47.1.88","article-title":"Heparin attenuates TNF-\u03b1 induced inflammatory response through a CD11b dependent mechanism","volume":"47","author":"Salas","year":"2000","journal-title":"Gut."},{"key":"B29","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/PL00000237","article-title":"Low molecular weight heparin inhibits tumor necrosis factor \u03b1-induced leukocyte rolling","volume":"50","author":"Wan","year":"2001","journal-title":"Inflamm Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/bjh.16727","article-title":"Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action","volume":"189","author":"Kollias","year":"2020","journal-title":"Br J Haematol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.thromres.2020.04.013","article-title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19","volume":"191","author":"Klok","year":"2020","journal-title":"Thromb Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"573044","DOI":"10.3389\/fphys.2020.573044","article-title":"Heparin therapy improving hypoxia in COVID-19 patients - a case series","volume":"11","author":"Negri","year":"2020","journal-title":"Front Physiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cell.2020.10.005","article-title":"Vascular disease and thrombosis in SARS-CoV-2-infected rhesus macaques","volume":"183","author":"Aid","year":"2020","journal-title":"Cell"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.3174\/AJNR.A6588","article-title":"Cerebrovascular disease in COVID-19","volume":"41","author":"Goldberg","year":"2020","journal-title":"Am J Neuroradiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000508958","article-title":"Cerebrovascular disease in patients with COVID-19: a review of the literature and case series","volume":"77030","author":"Reddy","year":"2020","journal-title":"Case Rep Neurol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/jth.14817","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","volume":"18","author":"Tang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1101\/2020.03.28.20046144","article-title":"The potential of low molecular weight heparin to mitigate cytokine storm in severe covid-19 patients: a retrospective clinical study","volume":"13","author":"Shi","year":"2020","journal-title":"Clin Transl Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/bcp.14714","article-title":"INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID-19 (INHALE-HEP): protocol and statistical analysis plan for an investigator-initiated international meta-trial of randomised studies","volume":"39","author":"Van Haren","year":"2020","journal-title":"Br J Clin Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/jth.12047","article-title":"Bronchoalveolar hemostasis in lung injury and acute respiratory distress syndrome","volume":"11","author":"Glas","year":"2013","journal-title":"J Thromb Haemost."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1001\/archinte.162.22.2537","article-title":"Thrombolysis vs heparin in the treatment of pulmonary embolism: a clinical outcome-based meta-analysis","volume":"162","author":"Agnelli","year":"2002","journal-title":"Arch Intern Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jaut.2020.102452","article-title":"Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?","volume":"111","author":"Liu","year":"2020","journal-title":"J Autoimmun."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e653","DOI":"10.1016\/S2665-9913(20)30309-X","article-title":"Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment","volume":"2","author":"Robinson","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/molehr\/gas060","article-title":"Heparin inhibits TNF-\u03b1 signaling in human endometrial stromal cells by interaction with NF-kB","volume":"19","author":"Spratte","year":"2013","journal-title":"Mol Hum Reprod."},{"key":"B45","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/j.1365-2141.2006.05959.x","article-title":"LMWH inhibits TNF-\u03b1 and IL-6 in placental villous explants and its effects are attenuated by TLR-4\/NF-\u03baB p65 blocking in JEG-3 cells","volume":"11","author":"Zhang","year":"2018","journal-title":"Int J Clin Exp Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0126763","article-title":"In-vitro suppression of IL-6 and IL-8 release from human pulmonary epithelial cells by non-anticoagulant fraction of enoxaparin","volume":"10","author":"Shastri","year":"2015","journal-title":"PLoS ONE."},{"key":"B47","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41577-020-0320-7","article-title":"Complement as a target in COVID-19?","volume":"20","author":"Risitano","year":"2020","journal-title":"Nat Rev Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2020.04.007","article-title":"Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases","volume":"220","author":"Magro","year":"2020","journal-title":"Transl Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1016\/j.thromres.2009.11.030","article-title":"Low-molecular-weight heparin inhibition in classical complement activaton pathway during pregnancy","volume":"125","author":"Oberkersch","year":"2010","journal-title":"Thromb Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbagen.2005.08.003","article-title":"Munoz, R. Erik Edens RJL. Kinetic studies on the interactions of heparin and complement proteins using surface plasmon resonance","volume":"23","author":"Haining","year":"2014","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/236345","article-title":"Eicosanoids and respiratory viral infection: coordinators of inflammation and potential therapeutic targets","volume":"2012","author":"McCarthy","year":"2012","journal-title":"Mediators Inflamm"},{"key":"B52","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1086\/590499","article-title":"Hyperinduction of cyclooxygenase-2-mediated proinflammatory cascade: a mechanism for the pathogenesis of avian influenza H5N1 infection","volume":"198","author":"Lee","year":"2008","journal-title":"J Infect Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jpeds.2004.03.049","article-title":"Airway eicosanoids in acute severe respiratory syncytial virus bronchiolitis","volume":"145","author":"Sznajer","year":"2004","journal-title":"J Pediatr."},{"key":"B54","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/j.1365-2222.2007.02733.x","article-title":"Human bronchial epithelial cells express an active and inducible biosynthetic pathway for leukotrienes B4 and C4","volume":"37","author":"Jame","year":"2007","journal-title":"Clin Exp Allergy."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1016\/j.ajpath.2020.06.010","article-title":"Eicosanoids: the overlooked storm in coronavirus disease 2019 (COVID-19)?","volume":"190","author":"Hammock","year":"2020","journal-title":"Am J Pathol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.athoracsur.2004.08.015","article-title":"Differential effect of heparin coating and complement inhibition on artificial surface-induced eicosanoid production","volume":"79","author":"Lappeg\u00e5rd","year":"2005","journal-title":"Ann Thorac Surg."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1164\/ajrccm.161.6.9907013","article-title":"Heparin inhibits eicosanoid metabolism and hyperventilation-induced bronchoconstriction in dogs","volume":"161","author":"Suzuki","year":"2000","journal-title":"Am J Respir Crit Care Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/j.1749-6632.1989.tb22523.x","article-title":"Antiviral activity of heparin and dextran sulfate against human immunodeficiency virus (HIV) in vitro","volume":"556","author":"Baba","year":"1989","journal-title":"Ann N Y Acad Sci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1128\/JB.87.5.1060-1066.1964","article-title":"Inhibitory effect of heparin on herpes simplex virus","volume":"87","author":"Nahmias","year":"1964","journal-title":"J Bacteriol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.antiviral.2016.12.023","article-title":"Heparin prevents Zika virus induced-cytopathic effects in human neural progenitor cells","volume":"140","author":"Ghezzi","year":"2017","journal-title":"Antiviral Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1055\/s-0040-1721319","article-title":"Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the surface protein (spike) S1 receptor binding domain with heparin","volume":"12","author":"Mycroft-West","year":"2020","journal-title":"Thromb Haemost"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/2020.05.21.107870","article-title":"Unfractionated heparin potently inhibits the binding of SARS-CoV-2 spike protein to a human cell line","volume":"21","author":"Partridge","year":"2020","journal-title":"bioRxiv"},{"key":"B63","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/bph.15304","article-title":"Unfractionated heparin inhibits live wild-type SARSCoV-2 cell infectivity at therapeutically relevant concentrations","volume":"178","author":"Tree","year":"2020","journal-title":"Br J Pharmacol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41421-020-00192-8","article-title":"Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro","volume":"6","author":"Kwon","year":"2020","journal-title":"Cell Discov."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.cell.2020.09.033","article-title":"SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2","volume":"7","author":"Clausen","year":"2020","journal-title":"Cell."},{"key":"B66","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.htct.2020.06.001","article-title":"Guidance on diagnosis, prevention and treatment of thromboembolic complications in COVID-19: a position paper of the Brazilian Society of thrombosis and hemostasis and the thrombosis and hemostasis committee of the brazilian association of hematology, hemotherapy and cellular therapy","volume":"42","author":"Orsi","year":"2020","journal-title":"Hematol Transfus Cell Ther."},{"key":"B67","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2015432","article-title":"Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19","volume":"383","author":"Ackermann","year":"2020","journal-title":"N Engl J Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M20-2003","article-title":"Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study","volume":"173","author":"Wichmann","year":"2020","journal-title":"Ann Intern Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"ITC1","DOI":"10.7326\/AITC202001070","article-title":"Annals of internal medicine\u00ae","volume":"172","author":"Rubin","year":"2020","journal-title":"Ann Intern Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.3201\/eid2609.201353","article-title":"Clinicopathologic and immunohistochemical findings from autopsy of patient with COVID-19, Japan","volume":"26","author":"Adachi","year":"2020","journal-title":"Emerg Infect Dis."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem.20200652","article-title":"Targeting potential drivers of COVID-19: neutrophil extracellular traps","volume":"217","author":"Barnes","year":"2020","journal-title":"J Exp Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/01.CCM.0000057846.21303.AB","article-title":"Coagulation, fibrinolysis, and fibrin deposition in acute lung injury","volume":"31","author":"Idell","year":"2003","journal-title":"Crit Care Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/rr86","article-title":"Surfactant alteration and replacement in acute respiratory distress syndrome","volume":"2","author":"G\u00fcnther","year":"2001","journal-title":"Respir Res."},{"key":"B74","first-page":"704","article-title":"Use of dexamethasone and prednisone in acute asthma exacerbations in pediatric patients","volume":"55","author":"Shefrin","year":"2009","journal-title":"Can Fam Physician."},{"key":"B75","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1164\/rccm.202006-2598LE","article-title":"COVID-19-associated acute respiratory distress syndrome clarified: a vascular endotype?","volume":"202","author":"Mangalmurti","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"B76","doi-asserted-by":"publisher","first-page":"102523","DOI":"10.1016\/j.autrev.2020.102523","article-title":"COVID-19 infection and rheumatoid arthritis: Faraway, so close!","volume":"19","author":"Favalli","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B77","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cyto.2018.01.025","article-title":"Cytokine MERS-CoV infection in humans is associated with a pro-in fl ammatory Th1 and Th17 cytokine profile","volume":"104","author":"Mahallawi","year":"2018","journal-title":"Cytokine"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/s41418-020-0530-3","article-title":"COVID-19 infection: the perspectives on immune responses","volume":"27","author":"Shi","year":"2020","journal-title":"Cell Death Differ"},{"key":"B79","doi-asserted-by":"publisher","first-page":"655","DOI":"10.4187\/respcare.06314","article-title":"Clinical pharmacology of corticosteroids","volume":"63","author":"Williams","year":"2018","journal-title":"Respir Care."},{"key":"B80","first-page":"396","article-title":"Soft glucocorticoid design: structural elements and physicochemical parameters determining receptor-binding affinity","volume":"59","author":"Buchwald","year":"","journal-title":"Pharmazie"},{"key":"B81","first-page":"2","article-title":"\u201cCorticosteroids and their use in respiratory disorders,\u201d","volume-title":"Corticosteroids, Vol. 55","author":"Janahi","year":"2017"},{"key":"B82","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nrm.2016.122","article-title":"Nuclear receptors outside the nucleus: extranuclear signalling by steroid receptors","volume":"17","author":"Levin","year":"2016","journal-title":"Nat Rev Mol Cell Biol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1042\/CS20171505","article-title":"Defining the role of glucocorticoids in inflammation","volume":"132","author":"Ronchetti","year":"2018","journal-title":"Clin Sci."},{"key":"B84","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1677\/jme.0.0280069","article-title":"Negative regulation of nuclear factor-\u03baB activation and function by glucocorticoids","volume":"28","author":"Almawi","year":"2002","journal-title":"J Mol Endocrinol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1042\/bj3180325","article-title":"Down-regulation of cytokine-induced cyclo-oxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation","volume":"318","author":"Ristim\u00e4ki","year":"1996","journal-title":"Biochem J."},{"key":"B86","unstructured":"JohnsonDB\n            LopezMJ\n            KelleyB\n          Treasure Island, FLStatPearls PublishingDexamethasone2020"},{"key":"B87","unstructured":"YasirM\n            SonthaliaS\n          30285357StatPearls PublishingCorticosteroid Adverse Effects2019"},{"key":"B88","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000362724","article-title":"One hormone, two actions: anti- and pro-inflammatory effects of glucocorticoids","volume":"22","author":"Cruz-Topete","year":"2014","journal-title":"Neuroimmunomodulation"},{"key":"B89","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/1941874412458678","article-title":"Glucocorticoids: complications to anticipate and prevent","volume":"3","author":"Gensler","year":"2013","journal-title":"Neurohospitalist."},{"key":"B90","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.mce.2013.03.003","article-title":"Metabolic functions of glucocorticoid receptor in skeletal muscle","volume":"380","author":"Kuo","year":"2016","journal-title":"Mol Cell Endocrinol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term systemic corticosteroid exposure : a systematic literature review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin Ther."},{"key":"B92","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11428-016-0070-0","article-title":"Glucocorticoids and diabetes","volume":"12","author":"Willms","year":"2016","journal-title":"Diabetologe."},{"key":"B93","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Comment clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","volume":"6736","author":"Russell","year":"2020","journal-title":"Lancet."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jama.2020.6019","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","volume":"2019","author":"Sanders","year":"2020","journal-title":"J Am Med Assoc"},{"key":"B95","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1164\/rccm.201712-2371ED","article-title":"Systemic corticosteroid therapy may delay viral clearance in patients with middle east respiratory syndrome coronavirus infection","volume":"197","author":"Hui","year":"2018","journal-title":"Am J Respir Crit Care Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13054-019-2395-8","article-title":"The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis","volume":"23","author":"Ni","year":"2019","journal-title":"Crit Care."},{"key":"B97","doi-asserted-by":"publisher","first-page":"13681","DOI":"10.1128\/JVI.01702-07","article-title":"Altered pathogenesis of porcine respiratory coronavirus in pigs due to immunosuppressive effects of dexamethasone: implications for corticosteroid use in treatment of severe acute respiratory syndrome coronavirus","volume":"81","author":"Jung","year":"2007","journal-title":"J Virol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1378\/chest.08-2408","article-title":"Activation and regulation of systemic inflammation in ARDS rationale for prolonged glucocorticoid therapy","volume":"136","author":"Meduri","year":"2009","journal-title":"Chest."},{"key":"B99","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S2213-2600(19)30417-5","article-title":"Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial","volume":"8","author":"Villar","year":"2020","journal-title":"Lancet Respir Med."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2020.02145","article-title":"Re-analysis of single cell transcriptome reveals that the NR3C1-CXCL8-neutrophil axis determines the severity of COVID-19","volume":"11","author":"Park","year":"2020","journal-title":"Front Immunol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"2600","author":"Yang","year":"2020","journal-title":"Lancet Respir Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3332\/ecancer.2020.1023","article-title":"COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?","volume":"14","author":"Russell","year":"2020","journal-title":"Ecancermedicalscience."},{"key":"B104","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0140-6736(20)30361-5","article-title":"On the use of corticosteroids for 2019-nCoV pneumonia","volume":"395","author":"Shang","year":"2020","journal-title":"Lancet."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40779-020-0233-6","article-title":"A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)","volume":"7","author":"Jin","year":"2020","journal-title":"Mil Med Res."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1001\/jama.2020.17023","article-title":"Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis","volume":"324","author":"Sterne","year":"2020","journal-title":"J Am Med Assoc."},{"key":"B107","first-page":"39","article-title":"Short-term dexamethasone in Sars-CoV-2 patients","volume":"103","author":"Selvaraj","year":"2020","journal-title":"R I Med J"},{"key":"B108","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/nejmoa2021436","article-title":"Dexamethasone in Hospitalized Patients with Covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jama.2020.17021","article-title":"Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial","volume":"324","author":"Tomazini","year":"2020","journal-title":"J Am Med Assoc"},{"key":"B110","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1001\/jama.2020.13170","article-title":"COVID-19 and dexamethasone: a potential strategy to avoid steroid-related strongyloides hyperinfection","volume":"55455","author":"Stauffer","year":"2020","journal-title":"J Am Med Assoc."},{"key":"B111","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11845-020-02287-3","article-title":"Corticosteroids in diabetes patients infected with COVID-19","volume":"190","author":"Deng","year":"2021","journal-title":"Ir J Med Sci"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13037-018-0178-9","article-title":"Dexamethasone and postoperative hyperglycemia in diabetics undergoing elective hip or knee arthroplasty: a case control study in 238 patients","volume":"12","author":"O'Connell","year":"2018","journal-title":"Patient Saf Surg."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1213\/01.ANE.0000146943.45445.55","article-title":"Hyperglycemia in patients administered dexamethasone for craniotomy","volume":"100","author":"Lukins","year":"2005","journal-title":"Anesth Analg."},{"key":"B114","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.cmet.2020.07.007","article-title":"Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1\u03b1\/glycolysis-dependent axis","volume":"32","author":"Codo","year":"2020","journal-title":"Cell Metab"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00467-011-1928-4","article-title":"Glucocorticoid-induced hypertension","volume":"27","author":"Goodwin","year":"2012","journal-title":"Pediatr Nephrol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/hr.2009.118","article-title":"Hemodynamics of dexamethasone-induced hypertension in the rat","volume":"32","author":"Ong","year":"2009","journal-title":"Hypertens Res."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnins.2019.01305","article-title":"Dexamethasone causes hypertension in rats even under chemical blockade of peripheral sympathetic nerves","volume":"13","author":"Soto-Pi\u00f1a","year":"2019","journal-title":"Front Neurosci."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.615333\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T04:33:00Z","timestamp":1619152380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.615333\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,23]]},"references-count":117,"alternative-id":["10.3389\/fmed.2021.615333"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.615333","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,23]]},"article-number":"615333"}}